Literature DB >> 7106698

Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia.

I A Hughes, G F Read.   

Abstract

The mean age at menarche in 6 girls on treatment for congenital adrenal hyperplasia from infancy was 13.6 years (range 12.6-14.5 years). Menarche or regular menses did not occur until plasma testosterone concentrations were within normal limits. This was achieved using single daily dexamethasone, 0.25-0.75 mg/day. The potency of this glucocorticoid in suppressing adrenal steroid biosynthesis relative to cortisol is about 80:1. The onset of regular, ovulatory menstrual cycles, as judged by daily salivary progesterone profiles, was achieved within 2-3 years of menarche using this treatment regimen. Such patients have a good prognosis for normal fertility.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106698     DOI: 10.1159/000179489

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  5 in total

Review 1.  Management of congenital adrenal hyperplasia.

Authors:  I A Hughes
Journal:  Arch Dis Child       Date:  1988-11       Impact factor: 3.791

Review 2.  Adrenal steroidogenesis and congenital adrenal hyperplasia.

Authors:  Adina F Turcu; Richard J Auchus
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06       Impact factor: 4.741

3.  Steroids and growth.

Authors:  I A Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-19

4.  Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the "growth toxic" glucocorticoid.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-04-15

5.  Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.

Authors:  Anne Bachelot; Zeina Chakhtoura; Dinane Samara-Boustani; Jérome Dulon; Philippe Touraine; Michel Polak
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.